WHO Says Actively Engaging With Swedish Health Authorities On Managing First Confirmed Case Of Mpox Clade Ib, Our Advice To Member States Going Forward
Portfolio Pulse from Benzinga Newsdesk
The World Health Organization (WHO) is actively engaging with Swedish health authorities to manage the first confirmed case of Mpox Clade Ib. The WHO has also provided advice to member states on how to proceed.
August 15, 2024 | 4:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aethlon Medical (AEMD) may see increased interest due to its focus on infectious disease treatments, as WHO engages with Sweden on Mpox Clade Ib.
AEMD focuses on infectious disease treatments, and the WHO's engagement on Mpox Clade Ib could drive interest in companies working in this area.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Chimerix (CMRX) might experience a positive impact as the WHO's involvement in Mpox Clade Ib management could highlight the need for antiviral treatments.
CMRX develops antiviral treatments, and the WHO's actions on Mpox Clade Ib could increase demand for such solutions.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
GeoVax Labs (GOVX) could see a positive impact as the WHO's engagement on Mpox Clade Ib may boost interest in vaccine development.
GOVX is involved in vaccine development, and the WHO's involvement in managing Mpox Clade Ib could highlight the importance of vaccines.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Inovio Pharmaceuticals (INO) may benefit as the WHO's actions on Mpox Clade Ib could underscore the need for DNA-based vaccines.
INO develops DNA-based vaccines, and the WHO's engagement on Mpox Clade Ib could increase interest in such technologies.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Moderna (MRNA) might experience a positive impact as the WHO's involvement in Mpox Clade Ib management could highlight the need for mRNA vaccines.
MRNA develops mRNA vaccines, and the WHO's actions on Mpox Clade Ib could increase demand for such solutions.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
SIGA Technologies (SIGA) could see a positive impact as the WHO's engagement on Mpox Clade Ib may boost interest in antiviral treatments.
SIGA develops antiviral treatments, and the WHO's involvement in managing Mpox Clade Ib could highlight the importance of such solutions.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Tonix Pharmaceuticals (TNXP) may benefit as the WHO's actions on Mpox Clade Ib could underscore the need for treatments for infectious diseases.
TNXP focuses on treatments for infectious diseases, and the WHO's engagement on Mpox Clade Ib could increase interest in such solutions.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50